Entering text into the input field will update the search result below

Teva offers EU concessions for Allergan deal

  • According to EU regulators, Teva Pharmaceutical (NYSE:TEVA) has offered concessions to allay antitrust concerns over its $40.5B bid for Allergan's (NYSE:AGN) generics unit.
  • "Commitments have been submitted and the new legal deadline is set on 10 March," European Commission spokesman Ricardo Cardoso said in an email.
  • Acquiring the Actavis generic business would strengthen Teva's position as the world's largest generics drugmaker.

Recommended For You

More Trending News

About TEVA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TEVA--
Teva Pharmaceutical Industries Limited